10
June
2021
|
17:41 PM
America/New_York

Orgenesis to trial Tissue Genesis Icellator tech for cell recovery

Manufacturing Chemist reports the enrollment has begun for phase 2 of a randomized, placebo-controlled clinical trial, to evaluate autologous stromal and vascular fraction cell (SVF) injections after rotator cuff surgery, led by principal investigator Scott A. Rodeo, MD, sports medicine surgeon at HSS.

Dr. Rodeo said, “I am pleased to lead this trial investigating the efficacy of Icellator-generated SVF in patients after rotator cuff repair. There is a significant clinical need to improve outcomes for these patients and SVF injection has shown promise in early research.”

Read the full article at ManufacturingChemist.com.

Additional coverage: BeckersSpine.com